SMMT
Summit Therapeutics Inc.
FDA PDUFA Target Action Date
Saturday, November 14, 2026
172 days away
Drug Information
- Drug Name
- Ivonescimab + chemotherapy (CT.gov)
- Application Type
- BLA
- FDA Designations
- Fast TrackBreakthrough
- Indication
- EGFR-mutated NSCLC post-TKI therapy (combination with platinum-doublet chemo)
Filing Details
- Company
- Summit Therapeutics Inc.
- Stock Ticker
- SMMT
- SEC CIK
- 0001599298
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Track All FDA Decisions
View all upcoming PDUFA dates and AdCom meetings on our FDA Calendar.
View FDA Calendar →Data sourced from SEC EDGAR filings. Last updated: 2026-04-10. Report an issue